

Journal Recommendations Report

Prepared by: *Sample*

G0000-00000-Sample-FS

Manuscript title: **Effect of hematocrit on tacrolimus concentration**

Therapeutic Drug Monitoring (Ther Drug Monit)

Impact factor: 1.926

Published bimonthly (6 issues/year) by Wolters Kluwer, online and in print. Open access option.

Readership

A global audience of clinicians and related healthcare professionals practicing in all fields of transplant clinical medicine and biology.

Aims and scope

Therapeutic Drug Monitoring publishes studies detailing the various factors that affect the rate and extent that drugs are absorbed, metabolized, and excreted.

Relevant publications

Karim A, Zohra C, Mouna H, et al. Development of limited sampling strategies for the estimation of tacrolimus area under the curve in adult kidney transplant recipients according to the post transplantation time. *Ther Drug Monit.* 2015 Aug;37(4):524–30.

Indexed in:

Embase
Index Copernicus
JStage
MEDLINE
PubMed
PubMed Central
Science Citation Index Expanded
SCImago
Scopus

This is a multidisciplinary journal that publishes a wide range of manuscripts with a clinical focus that are of interest to pharmacologists, clinical chemists, pharmacists, drug researchers and toxicologists. The journal aims to foster the exchange of scientific understanding and new evidence in the field of therapeutic drug monitoring between the disciplines of clinical pharmacology, pathology, toxicology and analytical chemistry.

Yao X, Huang H, Wei C, et al. Limited sampling strategy for mycophenolic acid in Chinese kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus during the early post-transplantation phase. *Ther Drug Monit.* 2015 Aug;37(4):516–23.

It accepts a number of different article types, and you may wish to consider whether your manuscript would be suitable as an original article or a technical note.

Cai W, Ye C, Sun X et al. Limited sampling strategy for predicting area under the concentration-time curve for mycophenolic acid in Chinese adults receiving mycophenolate mofetil and tacrolimus early after renal transplantation. *Ther Drug Monit.* 2015 Jun;37(3):304–10.

Contacts

[Journal website](#)

Editor: Prof. Dr. med. Dr. H. C. Michael Oellerich

Published monthly (12 issues/year) by Informa Healthcare, online and in print. Open access option.

Readership	Aims and scope	Relevant publications
<p>A global audience of clinicians and basic scientists with an interest in all fields of transplant medicine and biology.</p>	<p>As well as publishing articles on clinical pharmacokinetics and metabolism, covering the absorption, distribution, metabolism and excretion of drugs in humans, <i>Xenobiotica</i> also publishes articles about animal pharmacokinetics and drug metabolism, and <i>in vitro</i> and molecular pharmacokinetic studies.</p>	<p>Zhu L, Yang J, Zhang Y, et al. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. <i>Xenobiotica</i>. 2015 Sept;45(9):840–6.</p>
<p>Indexed in:</p> <p>Biochemistry and Biophysics Citation Index BIOSIS Current Contents/Life Science EBSCO Index Medicus/MEDLINE/PubMed ISI Science Citation Index Expanded Pascal SciSearch Research Alert and Environmental Periodical Bibliography Russian Institute of Scientific, Technical Information Science Citation Index Chemical Abstracts</p>	<p>This journal publishes special issues in collaboration with the International Society for the Study of Xenobiotics.</p>	<p>Chitnis SD, Ogasawara K, Schniedewind B, et al. Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism. <i>Xenobiotica</i>. 2013 Jul;43(7):641–9.</p> <p>Ogawa K, Kato M, Houjo T, et al. A new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data. <i>Xenobiotica</i>. 2013 May;43(5):468–78.</p> <p>Patel CG, Ogasawara K, Akhlaghi F. Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus. <i>Xenobiotica</i>. 2013 Mar;43(3):229–35.</p>

Contacts

[Journal website](#)

Editor-in-Chief: Prof. Costas Ioannides

Published 10 times/year by Elsevier, in print and online. Open access option.

Readership

An audience of surgeons, physicians and basic scientists with an interest in organ, bone marrow and stem cell transplantation.

Indexed in:

BIOSIS Previews
Current Contents - Clinical Medicine
Current Contents - Life Sciences
CINAHL
EMBASE
Index Medicus
Medline
PubMed
PubMed Central
Scopus Cases Database
Science Citation Index
Science Citation Index Expanded

Aims and scope

Transplantation Proceedings publishes original articles in the field of transplantation biology and clinical medicine. The articles it publishes have a strong clinical focus.

The journal is also the official publication of a large number of global affiliated societies, including the Asian Transplantation Society. It publishes the proceedings of the annual congresses of these societies, so has a notably international emphasis.

You will see that it has recently published a number of studies concerning tacrolimus assays, so submission of your manuscript would fit well with this theme. Because your article is relatively concise, you may also wish to consider submitting it to their Clinical Transplantation Proceedings section, where the journal publishes rapid original contributions of preclinical and clinical experiences.

Relevant publications

Mita A, Ikegami T, Masuda Y, et al. Optimal initial dose of orally administered once-daily extended-release tacrolimus following intravenous tacrolimus therapy after liver transplantation. *Transpl P.* 2014 Apr;46(3):794–6.

Hashi S, Masuda S, Kikuchi M, et al. Assessment of four methodologies (microparticle enzyme immunoassay, chemiluminescent enzyme immunoassay, affinity column-mediated immunoassay, and flow injection assay-tandem mass spectrometry) for measuring tacrolimus blood concentration in Japanese liver transplant recipients. *Transpl P.* 2014 Apr;46(3):758–60.

Joo DJ, Jung I, Kim MS, et al. Comparison of the affinity column-mediated immunoassay and microparticle enzyme immunoassay methods as a tacrolimus concentration assay in the early period after liver transplantation. *Transpl P.* 2010 Dec;42(10):4137–40.

Ju MK, Chang HK, Kim HJ, et al. Is the affinity column-mediated immunoassay method suitable as an alternative to the microparticle enzyme immunoassay method as a blood tacrolimus assay? *Transpl P.* 2008 Dec;40(10):3673–8.

Contacts

[Journal website](#)

Editor-in-Chief: Dr. Barry Kahan

Published continuously by Springer, online only. Open access only.

Readership	Aims and scope	Relevant publications
<p>The open access nature of this journal means that it has a very wide audience; theoretically, anybody can read it. The main audience, however, is likely to be physicians, pharmacologists, toxicologists, basic scientists and allied health professionals with an interest in the field.</p>	<p><i>BMC Pharmacology and Toxicology</i> publishes articles on all aspects of chemically defined therapeutic and toxic agents, including both experimental and clinical studies.</p> <p>The BMC journals have an excellent reputation for prompt decision making, so your manuscript—if deemed suitable—is likely to be published quickly.</p>	<p>Madian AG, Panigrahi A, Perera MA, et al. Case report: Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution. <i>BMC Pharmacol Toxicol</i>. 2014 Dec;15:69.</p> <p>Ostermann H, Solano C, Jarque I, et al. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain. <i>BMC Pharmacol Toxicol</i>. 2014 Sep;15:52.</p>
<p>Indexed in:</p> <p>CABI CAS Current contents Embase Index Copernicus MEDLINE PubMed PubMed Central Science Citation Index Expanded SCImago Scirus Scopus Zetoc and others</p>	<p>Publishing your work as an open-access article means that it is more likely to be cited, and that all physicians working in your field will be able to access your work. However, publication in <i>BMC Pharmacology and Toxicology</i> has a charge of US\$2,145 prior to publication.</p> <p>Journals that publish large numbers of papers are less likely to have a high impact factor. <i>BMC Pharmacology and Toxicology</i> is a relatively new journal and has recently applied for an impact factor. It has not yet been calculated, but will likely be in the region of 1.</p>	<p>Crobu D, Spinetti G, Schrepfer R, et al. Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®. <i>BMC Pharmacol Toxicol</i>. 2014 Feb;15:7.</p> <p>Ratcliffe MJ, Dougall IG. Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages. <i>BMC Pharmacol Toxicol</i>. 2012 Nov;13:1.</p>

Contacts

[Journal website](#)

Executive Editor: Christopher Morrey

Terminology

Publishing frequency	The number of times the journal is published each year. More frequent publishing usually means the journal can publish more manuscripts each year. This may also affect the anticipated time to publication once the manuscript is accepted.
Publication type	This indicates whether the journal is published in print form only (the journal is only posted to subscribers), online only (issues are available online to subscribers or to those who buy access to a specific manuscript) or both (the journal is available both in print and online).
Open access	Many journals also offer open access online. This means that the journal (or specific manuscripts) can be read by anyone, not just subscribers. However, journals often charge a fee for open access, which is charged to the author.
Impact factor	The Impact factor cited by the journal, as prepared for the Journal Citation Report.
Readership	A summary of who is likely to read the journal. Where available, we will also indicate the number of subscribers to that journal.
Aims and scope	A summary of the aims and scope of the journal, including the subject areas and types of manuscripts published (e.g., Letters to the Editor, Short/Brief Communications, Full articles).
Rejection rate	Where possible, we will state what percentage of the manuscripts submitted to the journal are rejected. Not all journals state this information.
Lead times	Where possible, we will state (1) how long peer review takes and (2) how quickly the manuscript is published on acceptance. Shorter lead times mean your manuscript will be reviewed and published quicker (if accepted). Some journals offer 'rapid pre-publication' of accepted manuscripts, which are unformatted and non-final versions.
Relevant publications	A list of related studies that have been published in the journal. Some studies are identified based on the literature cited in your manuscript; others are identified using selected keywords.